PI3K/Akt/mTOR Pathway and Its Role in Cancer Therapeutics: Are We Making Headway?

Cancer is a severe public health issue that is a leading cause of mortality globally. It is also an impediment to improving life expectancy worldwide. Furthermore, the global burden of cancer incidence and death is continuously growing. Current therapeutic options are insufficient for patients, and...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in oncology Vol. 12; p. 819128
Main Authors Peng, Yan, Wang, Yuanyuan, Zhou, Cheng, Mei, Wuxuan, Zeng, Changchun
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 24.03.2022
Subjects
cancer
oncogenic alterations
Oncology
PI3K/Akt/mTOR pathway
precision medicine
targeted therapy
oncogenic alterations
targeted therapy
precision medicine
cancer
PI3K/Akt/mTOR pathway
Online AccessGet full text

Cover

Abstract Cancer is a severe public health issue that is a leading cause of mortality globally. It is also an impediment to improving life expectancy worldwide. Furthermore, the global burden of cancer incidence and death is continuously growing. Current therapeutic options are insufficient for patients, and tumor complexity and heterogeneity necessitate customized medicine or targeted therapy. It is critical to identify potential cancer therapeutic targets. Aberrant activation of the PI3K/AKT/mTOR pathway has a significant role in carcinogenesis. This review summarized oncogenic PI3K/Akt/mTOR pathway alterations in cancer and various cancer hallmarks associated with the PI3K/AKT/mTOR pathway, such as cell proliferation, autophagy, apoptosis, angiogenesis, epithelial-to-mesenchymal transition (EMT), and chemoresistance. Importantly, this review provided recent advances in PI3K/AKT/mTOR inhibitor research. Overall, an in-depth understanding of the association between the PI3K/AKT/mTOR pathway and tumorigenesis and the development of therapies targeting the PI3K/AKT/mTOR pathway will help make clinical decisions.
AbstractList Cancer is a severe public health issue that is a leading cause of mortality globally. It is also an impediment to improving life expectancy worldwide. Furthermore, the global burden of cancer incidence and death is continuously growing. Current therapeutic options are insufficient for patients, and tumor complexity and heterogeneity necessitate customized medicine or targeted therapy. It is critical to identify potential cancer therapeutic targets. Aberrant activation of the PI3K/AKT/mTOR pathway has a significant role in carcinogenesis. This review summarized oncogenic PI3K/Akt/mTOR pathway alterations in cancer and various cancer hallmarks associated with the PI3K/AKT/mTOR pathway, such as cell proliferation, autophagy, apoptosis, angiogenesis, epithelial-to-mesenchymal transition (EMT), and chemoresistance. Importantly, this review provided recent advances in PI3K/AKT/mTOR inhibitor research. Overall, an in-depth understanding of the association between the PI3K/AKT/mTOR pathway and tumorigenesis and the development of therapies targeting the PI3K/AKT/mTOR pathway will help make clinical decisions.Cancer is a severe public health issue that is a leading cause of mortality globally. It is also an impediment to improving life expectancy worldwide. Furthermore, the global burden of cancer incidence and death is continuously growing. Current therapeutic options are insufficient for patients, and tumor complexity and heterogeneity necessitate customized medicine or targeted therapy. It is critical to identify potential cancer therapeutic targets. Aberrant activation of the PI3K/AKT/mTOR pathway has a significant role in carcinogenesis. This review summarized oncogenic PI3K/Akt/mTOR pathway alterations in cancer and various cancer hallmarks associated with the PI3K/AKT/mTOR pathway, such as cell proliferation, autophagy, apoptosis, angiogenesis, epithelial-to-mesenchymal transition (EMT), and chemoresistance. Importantly, this review provided recent advances in PI3K/AKT/mTOR inhibitor research. Overall, an in-depth understanding of the association between the PI3K/AKT/mTOR pathway and tumorigenesis and the development of therapies targeting the PI3K/AKT/mTOR pathway will help make clinical decisions.
Cancer is a severe public health issue that is a leading cause of mortality globally. It is also an impediment to improving life expectancy worldwide. Furthermore, the global burden of cancer incidence and death is continuously growing. Current therapeutic options are insufficient for patients, and tumor complexity and heterogeneity necessitate customized medicine or targeted therapy. It is critical to identify potential cancer therapeutic targets. Aberrant activation of the PI3K/AKT/mTOR pathway has a significant role in carcinogenesis. This review summarized oncogenic PI3K/Akt/mTOR pathway alterations in cancer and various cancer hallmarks associated with the PI3K/AKT/mTOR pathway, such as cell proliferation, autophagy, apoptosis, angiogenesis, epithelial-to-mesenchymal transition (EMT), and chemoresistance. Importantly, this review provided recent advances in PI3K/AKT/mTOR inhibitor research. Overall, an in-depth understanding of the association between the PI3K/AKT/mTOR pathway and tumorigenesis and the development of therapies targeting the PI3K/AKT/mTOR pathway will help make clinical decisions.
Author Wang, Yuanyuan
Peng, Yan
Zhou, Cheng
Mei, Wuxuan
Zeng, Changchun
AuthorAffiliation 2 Xianning Medical College, Hubei University of Science and Technology , Xianning , China
1 Department of Obstetrics, Longhua District Central Hospital , Shenzhen , China
3 Department of Medical Laboratory, Shenzhen Longhua District Central Hospital, Guangdong Medical University , Shenzhen , China
AuthorAffiliation_xml – name: 3 Department of Medical Laboratory, Shenzhen Longhua District Central Hospital, Guangdong Medical University , Shenzhen , China
– name: 1 Department of Obstetrics, Longhua District Central Hospital , Shenzhen , China
– name: 2 Xianning Medical College, Hubei University of Science and Technology , Xianning , China
Author_xml – sequence: 1
  givenname: Yan
  surname: Peng
  fullname: Peng, Yan
– sequence: 2
  givenname: Yuanyuan
  surname: Wang
  fullname: Wang, Yuanyuan
– sequence: 3
  givenname: Cheng
  surname: Zhou
  fullname: Zhou, Cheng
– sequence: 4
  givenname: Wuxuan
  surname: Mei
  fullname: Mei, Wuxuan
– sequence: 5
  givenname: Changchun
  surname: Zeng
  fullname: Zeng, Changchun
BackLink https://www.ncbi.nlm.nih.gov/pubmed/35402264$$D View this record in MEDLINE/PubMed
BookMark eNp1kUtvEzEUhS1UREvonhXykk0SP-ZlFqAoAhpR1FIFwc66Y18nbifjYE9A_fc4pEUtEt7Ysu_5jnXOc3LUhx4JecnZRMpGTV3ozUQwISYNV1w0T8iJELIYq0J-P3pwPianKV2zvKqScSafkWNZFllXFSfky-VCfprObobpZnlxRS9hWP-CWwq9pYsh0avQIfU9nUNvMNLlGiNscTd4k97QWUT6DelnuPH9ip4h2Cx994I8ddAlPL3bR-Trh_fL-dn4_OLjYj47H5tSNMO4dLxUdW2stYI13CmUqJxpBdTIQGHFq6aWrbKowHEngQu0FRMgVF1knRyRxYFrA1zrbfQbiLc6gNd_LkJcaYj5ox3qnEQrVIucu7Jwrmpa21Z1rYQoMPMxs94eWNtdu0FrsB8idI-gj196v9ar8FM3qqmLHPKIvL4DxPBjh2nQG58Mdh30GHZJ56yVKCtRlHn01UOvvyb3neSB6jBgYkgpotPGDzD4sLf2neZM7_vX-_71vn996D8L2T_Ce_Z_Jb8BXbKyBw
CitedBy_id crossref_primary_10_1080_23723556_2024_2351622
crossref_primary_10_1186_s40364_022_00397_x
crossref_primary_10_1142_S0192415X2550017X
crossref_primary_10_18632_aging_204616
crossref_primary_10_3390_cancers15153948
crossref_primary_10_3390_cancers16061137
crossref_primary_10_1167_iovs_65_11_1
crossref_primary_10_1093_jpp_rgae104
crossref_primary_10_1016_j_molcel_2023_10_017
crossref_primary_10_3389_fcell_2024_1372330
crossref_primary_10_1080_13543776_2024_2338100
crossref_primary_10_1080_15384047_2024_2431136
crossref_primary_10_1186_s12902_024_01703_4
crossref_primary_10_1186_s12958_024_01247_1
crossref_primary_10_2174_0109298673293028240326051835
crossref_primary_10_1186_s13045_024_01654_2
crossref_primary_10_1007_s00018_023_05089_9
crossref_primary_10_1371_journal_pone_0311419
crossref_primary_10_3390_md20110704
crossref_primary_10_1177_17588359241284911
crossref_primary_10_3892_ijmm_2024_5408
crossref_primary_10_3389_fonc_2024_1424293
crossref_primary_10_3892_or_2023_8643
crossref_primary_10_1021_acs_molpharmaceut_3c00620
crossref_primary_10_18632_aging_204740
crossref_primary_10_2147_NSA_S469193
crossref_primary_10_3390_ph17101389
crossref_primary_10_3389_fphar_2024_1448381
crossref_primary_10_3389_fphar_2025_1496511
crossref_primary_10_1007_s12672_025_01998_2
crossref_primary_10_1177_09731296241286282
crossref_primary_10_3390_ijms26051910
crossref_primary_10_3390_ijms23169008
crossref_primary_10_1111_tog_12948
crossref_primary_10_1007_s00210_024_03328_9
crossref_primary_10_20960_revcancer_00094
crossref_primary_10_1177_12034754251322881
crossref_primary_10_3390_cancers15194835
crossref_primary_10_2147_DDDT_S492047
crossref_primary_10_1002_cbic_202400305
crossref_primary_10_3390_cancers16213612
crossref_primary_10_1007_s12032_025_02613_8
crossref_primary_10_3389_fonc_2024_1379986
crossref_primary_10_1007_s13679_023_00542_z
crossref_primary_10_1007_s00432_024_05862_8
crossref_primary_10_1158_1078_0432_CCR_23_2570
crossref_primary_10_1111_bcpt_14110
crossref_primary_10_3892_or_2025_8864
crossref_primary_10_1186_s12964_023_01400_0
crossref_primary_10_3390_ijms241511992
crossref_primary_10_1038_s43856_024_00710_9
crossref_primary_10_3390_ijms241814073
crossref_primary_10_1177_03946320241276336
crossref_primary_10_3390_ijms241310651
crossref_primary_10_1186_s12906_022_03727_6
crossref_primary_10_3892_mmr_2025_13468
crossref_primary_10_1021_acsomega_3c06110
crossref_primary_10_12677_wjcr_2024_144026
crossref_primary_10_1097_MD_0000000000037264
crossref_primary_10_1186_s12645_023_00212_8
crossref_primary_10_1002_cmdc_202400818
crossref_primary_10_1039_D4RA02222J
crossref_primary_10_3389_fimmu_2024_1493978
crossref_primary_10_1186_s13048_024_01377_5
crossref_primary_10_1002_jbt_70232
crossref_primary_10_1177_03915603231222081
crossref_primary_10_1038_s41420_024_02204_y
crossref_primary_10_1002_jcsm_13276
crossref_primary_10_3389_fonc_2024_1447666
crossref_primary_10_2174_0929867331666230818110812
crossref_primary_10_1038_s41598_024_71123_w
crossref_primary_10_3892_mmr_2025_13437
crossref_primary_10_7554_eLife_96257_3
crossref_primary_10_3389_fonc_2023_1298660
crossref_primary_10_1039_D2MO00025C
crossref_primary_10_1186_s12967_023_04478_9
crossref_primary_10_2174_0113862073280183240108113853
crossref_primary_10_3390_molecules29173994
crossref_primary_10_1002_1878_0261_13609
crossref_primary_10_3390_cancers15133506
crossref_primary_10_1002_cbin_12197
crossref_primary_10_3390_molecules29225450
crossref_primary_10_1038_s41598_024_82554_w
crossref_primary_10_3390_ijms252312868
crossref_primary_10_37349_etat_2024_00267
crossref_primary_10_3390_cells12182209
crossref_primary_10_1007_s12029_024_01160_1
crossref_primary_10_3390_ijms25084438
crossref_primary_10_1002_mc_23775
crossref_primary_10_1002_cac2_12597
crossref_primary_10_3390_ijms26041752
crossref_primary_10_4236_ojog_2024_1412152
crossref_primary_10_1080_10408398_2025_2468863
crossref_primary_10_1088_1748_605X_ad1dff
crossref_primary_10_17816_onco642288
crossref_primary_10_7554_eLife_96257
crossref_primary_10_1007_s12035_023_03787_w
crossref_primary_10_3390_ijms24043135
crossref_primary_10_1002_cmdc_202300272
crossref_primary_10_1002_cnr2_2078
crossref_primary_10_1155_2022_7223353
crossref_primary_10_3390_biomedicines12061286
crossref_primary_10_1007_s12032_025_02646_z
crossref_primary_10_1155_2022_8445093
crossref_primary_10_1007_s11064_022_03853_0
crossref_primary_10_3390_cells14050330
crossref_primary_10_3390_vetsci12020117
crossref_primary_10_3390_ph15121477
crossref_primary_10_3389_fimmu_2023_1282996
crossref_primary_10_2174_0113895575270904231129062137
crossref_primary_10_3390_ijms25031848
crossref_primary_10_3390_cancers16183192
crossref_primary_10_3390_ijms25126468
crossref_primary_10_1080_14786419_2024_2306917
crossref_primary_10_3892_ijo_2024_5610
crossref_primary_10_1007_s12035_024_04039_1
crossref_primary_10_3390_cells11091553
crossref_primary_10_3390_ani15030444
crossref_primary_10_1186_s12957_024_03600_5
crossref_primary_10_3390_ijms25136937
crossref_primary_10_1615_CritRevImmunol_2024052462
crossref_primary_10_3390_cimb44110350
crossref_primary_10_1007_s00210_023_02702_3
crossref_primary_10_3390_molecules29174280
crossref_primary_10_3389_fonc_2024_1438040
crossref_primary_10_20517_cdr_2023_21
crossref_primary_10_1080_1061186X_2024_2417189
crossref_primary_10_1002_ctm2_1464
crossref_primary_10_1002_cam4_7303
crossref_primary_10_3390_ph17121562
crossref_primary_10_3390_ph17121564
crossref_primary_10_1186_s12951_022_01740_y
crossref_primary_10_1186_s13578_024_01296_4
crossref_primary_10_53011_JMRO_2023_02_05
crossref_primary_10_1093_nargab_lqae042
crossref_primary_10_34133_research_0509
crossref_primary_10_3389_fimmu_2024_1416961
crossref_primary_10_3390_ijms25052529
crossref_primary_10_1186_s12935_025_03658_5
crossref_primary_10_20517_cdr_2024_166
crossref_primary_10_1007_s11030_022_10556_9
crossref_primary_10_1038_s41598_024_71644_4
crossref_primary_10_1186_s12979_024_00426_3
crossref_primary_10_1186_s12951_024_02684_1
crossref_primary_10_3390_ijms25105381
crossref_primary_10_1021_acsomega_3c09212
crossref_primary_10_3390_molecules29194770
crossref_primary_10_3389_fphar_2024_1423480
crossref_primary_10_3390_ijms26010415
crossref_primary_10_3390_cancers14215227
crossref_primary_10_3390_ijms25084479
crossref_primary_10_1002_cbin_12277
crossref_primary_10_3389_fphar_2023_1182788
crossref_primary_10_1158_1535_7163_MCT_23_0135
crossref_primary_10_1002_cbdv_202300847
crossref_primary_10_1186_s13020_024_00899_w
crossref_primary_10_3390_medicina61030518
crossref_primary_10_3892_ol_2024_14833
crossref_primary_10_1007_s11010_024_05161_3
crossref_primary_10_1007_s12264_024_01342_8
crossref_primary_10_3390_cancers16050885
crossref_primary_10_3390_diagnostics13182887
crossref_primary_10_3390_ijms241310952
crossref_primary_10_1039_D2RA07382J
crossref_primary_10_3390_metabo13111149
crossref_primary_10_1186_s12935_023_02995_7
crossref_primary_10_3390_cancers15092622
crossref_primary_10_1038_s41698_024_00589_8
crossref_primary_10_3390_ijms24032289
crossref_primary_10_3390_ijms26030955
crossref_primary_10_3390_ijms25041973
crossref_primary_10_3390_cells12152014
crossref_primary_10_1002_cam4_5435
crossref_primary_10_1186_s12906_023_04120_7
crossref_primary_10_3389_fphar_2023_1247800
crossref_primary_10_1177_11779322251316864
crossref_primary_10_3389_fphar_2025_1548672
crossref_primary_10_1021_acs_molpharmaceut_3c00333
crossref_primary_10_3390_ijms252312840
crossref_primary_10_1007_s12672_024_01040_x
crossref_primary_10_3389_fendo_2024_1465975
crossref_primary_10_3390_cancers15225339
crossref_primary_10_3390_ijms23158386
crossref_primary_10_3389_fonc_2022_1007509
crossref_primary_10_1177_15330338241271935
crossref_primary_10_3389_fonc_2023_1184079
crossref_primary_10_3390_cancers16040752
crossref_primary_10_15421_0224144
crossref_primary_10_1038_s41420_024_02150_9
crossref_primary_10_1002_fsn3_3487
crossref_primary_10_3390_kinasesphosphatases2040023
crossref_primary_10_2174_1381612829666230330105320
crossref_primary_10_1155_ancp_1115184
crossref_primary_10_1080_01635581_2024_2361964
crossref_primary_10_12677_acm_2025_153589
crossref_primary_10_3892_ijo_2024_5677
crossref_primary_10_1002_mco2_308
crossref_primary_10_3390_jcm11195891
crossref_primary_10_3390_cancers14153776
crossref_primary_10_3390_targets2040019
crossref_primary_10_1007_s12032_023_02201_8
crossref_primary_10_3390_targets2040018
crossref_primary_10_1007_s12094_024_03715_x
crossref_primary_10_3390_pharmaceutics15082130
crossref_primary_10_1080_16583655_2024_2361991
crossref_primary_10_1002_ptr_8228
crossref_primary_10_3390_cancers16162796
crossref_primary_10_1002_jbt_70166
crossref_primary_10_1111_cas_16063
crossref_primary_10_3390_kinasesphosphatases2020011
crossref_primary_10_1002_ardp_202400402
crossref_primary_10_3390_ijms241310910
crossref_primary_10_3390_life14030297
crossref_primary_10_1007_s12672_024_01003_2
crossref_primary_10_3390_foods13060919
crossref_primary_10_1080_09205063_2024_2429325
crossref_primary_10_1248_cpb_c23_00379
crossref_primary_10_3390_ijms23158801
crossref_primary_10_1016_j_isci_2024_109979
crossref_primary_10_1111_jcmm_18020
crossref_primary_10_1186_s12935_022_02781_x
crossref_primary_10_1002_smtd_202301281
crossref_primary_10_1186_s12885_024_12781_x
crossref_primary_10_1007_s43440_024_00581_w
crossref_primary_10_3390_ijms24043643
crossref_primary_10_1007_s00210_024_02985_0
crossref_primary_10_1002_bab_2716
crossref_primary_10_1038_s41598_025_91251_1
crossref_primary_10_3390_pharmaceutics15051408
crossref_primary_10_1002_rmv_2487
crossref_primary_10_2174_1568009623666230801094826
crossref_primary_10_3390_cimb46050294
crossref_primary_10_1038_s41598_025_93519_y
crossref_primary_10_1155_2022_6906380
crossref_primary_10_3390_biom12111565
crossref_primary_10_1080_15685551_2022_2164445
crossref_primary_10_1186_s12943_024_02019_6
crossref_primary_10_1186_s12967_023_04841_w
crossref_primary_10_3390_ijms24032652
crossref_primary_10_3390_ijms24086905
crossref_primary_10_1007_s12672_024_00875_8
crossref_primary_10_1002_bmc_5417
crossref_primary_10_1038_s41417_024_00762_y
crossref_primary_10_3390_ijms252212387
crossref_primary_10_1007_s11154_025_09945_w
crossref_primary_10_1039_D4MD00246F
crossref_primary_10_7717_peerj_17263
crossref_primary_10_3389_fimmu_2024_1476494
crossref_primary_10_1007_s00210_025_04009_x
crossref_primary_10_1186_s12917_024_04085_w
crossref_primary_10_3390_md22050227
crossref_primary_10_18632_aging_205735
crossref_primary_10_1002_cnr2_1966
crossref_primary_10_1089_ars_2022_0187
crossref_primary_10_3389_fgene_2022_905047
crossref_primary_10_1007_s12032_024_02551_x
crossref_primary_10_1186_s43556_022_00110_2
crossref_primary_10_3390_ijms231810854
Cites_doi 10.1200/JCO.19.01027
10.3390/ijms222011088
10.1001/jamaoncol.2020.6741
10.1038/nrm3330
10.1007/s11523-017-0482-9
10.1016/j.drudis.2015.06.010
10.1001/jamaoncol.2019.2526
10.3389/fphar.2021.662232
10.1016/j.ccell.2017.04.013
10.1161/CIRCRESAHA.116.308483
10.1186/s13045-017-0436-9
10.1038/s41573-021-00209-1
10.3390/cancers13143517
10.1186/s13045-021-01137-8
10.1038/nrc1753
10.1038/s41556-020-0554-4
10.1016/S1470-2045(19)30817-4
10.1016/j.ajpath.2018.11.013
10.21037/tlcr.2019.04.19
10.1038/s41419-021-03657-0
10.1093/neuonc/nou365
10.1016/S1470-2045(17)30450-3
10.3390/cancers13061478
10.3390/molecules23082047
10.1038/s41589-021-00813-7
10.1038/nrclinonc.2011.71
10.1242/jcs.095299
10.1158/2159-8290.CD-12-0095
10.1186/s12943-019-0954-x
10.3390/genes11070719
10.1038/s41571-020-0341-y
10.1634/theoncologist.2017-0144
10.1200/JCO.18.01207
10.3389/fnmol.2011.00051
10.1016/S1470-2045(17)30688-5
10.2147/vhrm.2006.2.3.213
10.1038/s41467-020-18504-7
10.1158/1078-0432.CCR-15-1110
10.3389/fonc.2019.00422
10.1038/nature23306
10.1016/j.canlet.2011.06.005
10.1096/fj.201901205RR
10.1158/1078-0432.CCR-13-0884
10.1074/jbc.R109.094003
10.1200/JCO.2006.10.5916
10.3390/ijms22073464
10.1002/1878-0261.12728
10.1038/onc.2016.363
10.1186/s12943-019-1030-2
10.3390/ijms21113818
10.1126/scisignal.2004088
10.1182/blood-2018-05-850461
10.1038/s41467-021-24811-4
10.3390/ijms21093285
10.3390/ijms20112767
10.1016/j.bbrc.2020.05.087
10.1158/1078-0432.CCR-12-0714
10.1074/jbc.M112.399485
10.1200/JCO.2017.75.4648
10.1038/s41422-020-00443-z
10.1186/1756-9966-30-87
10.1038/nature12634
10.1038/onc.2015.79
10.1007/s00018-021-03993-6
10.1038/nm.4333
10.1002/cncr.27608
10.1016/j.bbamcr.2019.118635
10.1200/JCO.2017.72.7107
10.3390/cancers12102972
10.1182/blood-2013-11-535047
10.1016/j.critrevonc.2021.103284
10.3390/ijms20225792
10.1038/s41568-019-0216-7
10.1038/s41588-020-00710-0
10.7150/thno.35561
10.1200/JCO.21.01152
10.1038/nrc3037
10.1056/NEJMoa1813904
10.1200/JCO.18.00915
10.1038/s41580-020-0237-9
10.1200/JCO.20.03433
10.1016/j.cell.2017.04.001
10.1016/j.ejca.2021.08.010
10.1186/s13058-020-01284-9
10.1038/s41392-021-00572-w
10.1186/s12885-019-5824-9
10.3390/cells10030659
10.3390/molecules26134100
10.1016/j.kint.2020.07.052
10.1111/nyas.14305
10.1016/j.ejphar.2021.173983
10.1158/0008-5472.CAN-15-1654
10.1016/j.ejca.2017.01.024
10.1158/1078-0432.CCR-21-1402
10.3390/cancers10020052
10.1158/2159-8290.CD-16-0512
10.1016/j.ccell.2018.01.021
10.1158/0008-5472.CAN-12-4282
10.1016/S0140-6736(21)00580-8
10.3389/fonc.2018.00248
10.1158/1078-0432.CCR-20-4131
10.1016/j.ccell.2019.01.020
10.1186/s12885-016-2626-1
10.1007/s00018-019-03351-7
10.1016/j.biochi.2019.08.003
10.1200/JCO.19.00368
10.1002/cncr.30286
10.3389/fcell.2020.573599
10.1073/pnas.1204384109
10.3390/ijms20030755
10.1165/rcmb.2020-0109ED
10.1200/JCO.20.01576
10.1016/j.semcancer.2019.07.003
10.1016/S1470-2045(17)30064-5
10.2147/OTT.S205160
10.3390/cancers13163949
10.1001/jamaoncol.2021.3428
10.1056/NEJMicm1910478
10.1200/JCO.2012.45.2003
10.1038/nrc839
10.1016/j.apsb.2020.01.010
ContentType Journal Article
Copyright Copyright © 2022 Peng, Wang, Zhou, Mei and Zeng.
Copyright © 2022 Peng, Wang, Zhou, Mei and Zeng 2022 Peng, Wang, Zhou, Mei and Zeng
Copyright_xml – notice: Copyright © 2022 Peng, Wang, Zhou, Mei and Zeng.
– notice: Copyright © 2022 Peng, Wang, Zhou, Mei and Zeng 2022 Peng, Wang, Zhou, Mei and Zeng
DBID AAYXX
CITATION
NPM
7X8
5PM
DOA
DOI 10.3389/fonc.2022.819128
DatabaseName CrossRef
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
PubMed
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic

PubMed

CrossRef
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2234-943X
ExternalDocumentID oai_doaj_org_article_234b29be11f54ff68bdb6779224ede9e
PMC8987494
35402264
10_3389_fonc_2022_819128
Genre Journal Article
Review
GrantInformation_xml – fundername: ;
  grantid: 81660755
– fundername: ;
  grantid: JCYJ20170307160524377, JCYJ20190808162605484
GroupedDBID 53G
5VS
9T4
AAFWJ
AAKDD
AAYXX
ACGFO
ACGFS
ACXDI
ADBBV
ADRAZ
AFPKN
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BCNDV
CITATION
DIK
EBS
EJD
EMOBN
GROUPED_DOAJ
GX1
HYE
KQ8
M48
M~E
OK1
PGMZT
RNS
RPM
IPNFZ
NPM
RIG
7X8
5PM
ID FETCH-LOGICAL-c528t-5f15977cddd2081f9e3e9fcb2a7e0a9e616873b9de9af1f3a12ed602a297477c3
IEDL.DBID M48
ISSN 2234-943X
IngestDate Wed Aug 27 01:29:01 EDT 2025
Thu Aug 21 18:13:08 EDT 2025
Fri Jul 11 05:03:11 EDT 2025
Thu Apr 03 07:00:48 EDT 2025
Thu Apr 24 23:01:17 EDT 2025
Tue Jul 01 02:46:31 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Keywords oncogenic alterations
targeted therapy
precision medicine
cancer
PI3K/Akt/mTOR pathway
Language English
License Copyright © 2022 Peng, Wang, Zhou, Mei and Zeng.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c528t-5f15977cddd2081f9e3e9fcb2a7e0a9e616873b9de9af1f3a12ed602a297477c3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
Reviewed by: Enrique Gonzalez Billalabeitia, Hospital Universitario 12 de Octubre, Spain; Xiaoyong Fu, Baylor College of Medicine, United States
Edited by: Yan-yan Yan, Shanxi Datong University, China
This article was submitted to Cancer Molecular Targets and Therapeutics, a section of the journal Frontiers in Oncology
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.3389/fonc.2022.819128
PMID 35402264
PQID 2649256245
PQPubID 23479
ParticipantIDs doaj_primary_oai_doaj_org_article_234b29be11f54ff68bdb6779224ede9e
pubmedcentral_primary_oai_pubmedcentral_nih_gov_8987494
proquest_miscellaneous_2649256245
pubmed_primary_35402264
crossref_citationtrail_10_3389_fonc_2022_819128
crossref_primary_10_3389_fonc_2022_819128
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2022-03-24
PublicationDateYYYYMMDD 2022-03-24
PublicationDate_xml – month: 03
  year: 2022
  text: 2022-03-24
  day: 24
PublicationDecade 2020
PublicationPlace Switzerland
PublicationPlace_xml – name: Switzerland
PublicationTitle Frontiers in oncology
PublicationTitleAlternate Front Oncol
PublicationYear 2022
Publisher Frontiers Media S.A
Publisher_xml – name: Frontiers Media S.A
References Salazar (B118) 2018; 23
Hao (B77) 2019; 20
Kandoth (B33) 2013; 502
Harsha (B15) 2020; 21
Dogruluk (B26) 2015; 75
Andre (B97) 2019; 380
Bian (B54) 2017; 9
Gao (B20) 2013; 6
Choi (B78) 2020; 528
Murugan (B81) 2019; 59
Zhang (B29) 2017; 31
Crabb (B101) 2021; 39
Lee (B3) 2021; 17
Chen (B40) 2020; 8
Jones (B102) 2020; 21
Kong (B30) 2016; 22
Vanhaesebroeck (B9) 2021; 20
Beaver (B39) 2013; 19
Mange (B52) 2019; 9
Hillmann (B116) 2019; 20
Saura (B104) 2017; 7
Fusco (B12) 2020; 11
Cerami (B21) 2012; 2
Hong (B88) 2012; 18
Hollander (B45) 2011; 11
Wang (B49) 2020; 34
Flinn (B95) 2018; 132
Ng (B27) 2018; 33
Makker (B122) 2016; 122
Hua (B10) 2021; 14
Soulieres (B92) 2017; 18
Flinn (B96) 2019; 37
Schmid (B111) 2019; 5
Luciani (B4) 2021; 99
Gonzalez-Angulo (B28) 2013; 119
Deng (B86) 2019; 19
Motzer (B109) 2007; 25
Al-Bari (B57) 2020; 1467
Chien (B107) 2020; 38
Song (B43) 2012; 13
Mishra (B115) 2021; 22
Zuazo-Gaztelu (B66) 2018; 8
Alexa (B47) 2021; 13
Kalinsky (B100) 2021; 7
Duan (B16) 2020; 12
Wong (B61) 2011; 30
Yip (B13) 2021; 10
Carneiro (B62) 2020; 17
Ji (B68) 2018; 23
Ma (B50) 2019; 35
Yang (B117) 2019; 18
Wise-Draper (B120) 2017; 12
Roche (B71) 2018; 10
Khorasani (B11) 2021; 898
Lamouille (B79) 2012; 125
Dreyling (B93) 2017; 35
Fan (B110) 2021; 7
Wipperman (B5) 2019; 189
Moliere (B46) 2020; 382
Iksen (B17) 2021; 26
Bader (B19) 2005; 5
Kim (B106) 2017; 18
Foster (B1) 2010; 285
Kim (B70) 2016; 119
Morscher (B113) 2021; 157
Colombo (B121) 2021; 27
Karar (B67) 2011; 4
Martinez-Saez (B25) 2020; 22
Choi (B48) 2021; 12
Rascio (B82) 2021; 13
Rudolph (B38) 2016; 16
Bolton (B24) 2020; 52
Komiya (B108) 2019; 8
Annunziata (B75) 2020; 21
Wu (B87) 2019; 9
Di Leo (B90) 2018; 19
Pitz (B89) 2015; 17
Wen (B91) 2019; 37
Wang (B69) 2019; 12
Brugarolas (B31) 2014; 32
Massard (B119) 2017; 76
Martorana (B8) 2021; 12
Murugan (B34) 2013; 288
Karimi Roshan (B76) 2019; 165
He (B63) 2016; 35
Gremke (B80) 2020; 11
Pereira (B42) 2015; 20
Yang (B72) 2020; 21
Lugano (B65) 2020; 77
Li (B6) 2021; 13
Tian (B51) 2019; 20
Sweeney (B105) 2021; 398
Cabezudo (B60) 2021; 12
Janku (B58) 2011; 8
Vivanco (B36) 2002; 2
Lu (B55) 2020; 10
Shen (B83) 2013; 73
Brown (B94) 2014; 123
Pungsrinont (B7) 2021; 22
Yoshida (B56) 2017; 10
Herrerias (B74) 2020; 62
Parikh (B37) 2012; 109
Hoxhaj (B14) 2020; 20
Nishida (B64) 2006; 2
Zehir (B22) 2017; 23
Xie (B44) 2021; 31
Bautista (B112) 2021; 39
Chen (B73) 2019; 18
Robinson (B23) 2017; 548
Fowler (B99) 2021; 39
Gaur (B84) 2011; 311
Schmid (B103) 2020; 38
Kim (B2) 2017; 36
Evangelisti (B53) 2020; 1867
Manning (B35) 2017; 169
Sharma (B41) 2021; 78
Juric (B98) 2018; 36
Lim (B114) 2021; 27
Zhong (B18) 2021; 6
Wu (B85) 2021; 15
Moura (B32) 2021; 160
Nowosad (B59) 2020; 22
References_xml – volume: 38
  year: 2020
  ident: B107
  article-title: MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.19.01027
– volume: 22
  start-page: 11088
  year: 2021
  ident: B7
  article-title: Role of PI3K-AKT-mTOR Pathway as a Pro-Survival Signaling and Resistance-Mediating Mechanism to Therapy of Prostate Cancer
  publication-title: Int J Mol Sci
  doi: 10.3390/ijms222011088
– volume: 7
  year: 2021
  ident: B100
  article-title: Effect of Capivasertib in Patients With an AKT1 E17K-Mutated Tumor: NCI-MATCH Subprotocol EAY131-Y Nonrandomized Trial
  publication-title: JAMA Oncol
  doi: 10.1001/jamaoncol.2020.6741
– volume: 13
  year: 2012
  ident: B43
  article-title: The Functions and Regulation of the PTEN Tumour Suppressor
  publication-title: Nat Rev Mol Cell Biol
  doi: 10.1038/nrm3330
– volume: 12
  year: 2017
  ident: B120
  article-title: A Phase Ib Study of the Dual PI3K/mTOR Inhibitor Dactolisib (BEZ235) Combined With Everolimus in Patients With Advanced Solid Malignancies
  publication-title: Target Oncol
  doi: 10.1007/s11523-017-0482-9
– volume: 20
  year: 2015
  ident: B42
  article-title: Implications of Akt2/Twist Crosstalk on Breast Cancer Metastatic Outcome
  publication-title: Drug Discov Today
  doi: 10.1016/j.drudis.2015.06.010
– volume: 5
  year: 2019
  ident: B111
  article-title: Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor-Positive Metastatic Breast Cancer: The MANTA Phase 2 Randomized Clinical Trial
  publication-title: JAMA Oncol
  doi: 10.1001/jamaoncol.2019.2526
– volume: 12
  year: 2021
  ident: B8
  article-title: AKT Inhibitors: New Weapons in the Fight Against Breast Cancer
  publication-title: Front Pharmacol
  doi: 10.3389/fphar.2021.662232
– volume: 31
  start-page: 820
  year: 2017
  ident: B29
  article-title: A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2017.04.013
– volume: 119
  year: 2016
  ident: B70
  article-title: SoxF Transcription Factors Are Positive Feedback Regulators of VEGF Signaling
  publication-title: Circ Res
  doi: 10.1161/CIRCRESAHA.116.308483
– volume: 10
  start-page: 67
  year: 2017
  ident: B56
  article-title: Therapeutic Strategies of Drug Repositioning Targeting Autophagy to Induce Cancer Cell Death: From Pathophysiology to Treatment
  publication-title: J Hematol Oncol
  doi: 10.1186/s13045-017-0436-9
– volume: 20
  year: 2021
  ident: B9
  article-title: PI3K Inhibitors are Finally Coming of Age
  publication-title: Nat Rev Drug Discov
  doi: 10.1038/s41573-021-00209-1
– volume: 13
  start-page: 3517
  year: 2021
  ident: B6
  article-title: Targeting PI3K/AKT/mTOR Signaling Pathway in Breast Cancer
  publication-title: Cancers (Basel)
  doi: 10.3390/cancers13143517
– volume: 14
  start-page: 128
  year: 2021
  ident: B10
  article-title: Targeting Akt in Cancer for Precision Therapy
  publication-title: J Hematol Oncol
  doi: 10.1186/s13045-021-01137-8
– volume: 5
  year: 2005
  ident: B19
  article-title: Oncogenic PI3K Deregulates Transcription and Translation
  publication-title: Nat Rev Cancer
  doi: 10.1038/nrc1753
– volume: 22
  year: 2020
  ident: B59
  article-title: P27 Controls Ragulator and mTOR Activity in Amino Acid-Deprived Cells to Regulate the Autophagy-Lysosomal Pathway and Coordinate Cell Cycle and Cell Growth
  publication-title: Nat Cell Biol
  doi: 10.1038/s41556-020-0554-4
– volume: 21
  year: 2020
  ident: B102
  article-title: Fulvestrant Plus Capivasertib Versus Placebo After Relapse or Progression on an Aromatase Inhibitor in Metastatic, Oestrogen Receptor-Positive Breast Cancer (FAKTION): A Multicentre, Randomised, Controlled, Phase 2 Trial
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(19)30817-4
– volume: 189
  start-page: 492
  year: 2019
  ident: B5
  article-title: Mammalian Target of Rapamycin: A Metabolic Rheostat for Regulating Adipose Tissue Function and Cardiovascular Health
  publication-title: Am J Pathol
  doi: 10.1016/j.ajpath.2018.11.013
– volume: 8
  year: 2019
  ident: B108
  article-title: A Phase I/II Study of Pemetrexed With Sirolimus in Advanced, Previously Treated Non-Small Cell Lung Cancer
  publication-title: Transl Lung Cancer Res
  doi: 10.21037/tlcr.2019.04.19
– volume: 12
  start-page: 374
  year: 2021
  ident: B48
  article-title: Mutation-Specific Non-Canonical Pathway of PTEN as a Distinct Therapeutic Target for Glioblastoma
  publication-title: Cell Death Dis
  doi: 10.1038/s41419-021-03657-0
– volume: 17
  year: 2015
  ident: B89
  article-title: Phase II Study of PX-866 in Recurrent Glioblastoma
  publication-title: Neuro Oncol
  doi: 10.1093/neuonc/nou365
– volume: 18
  year: 2017
  ident: B106
  article-title: Ipatasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel as First-Line Therapy for Metastatic Triple-Negative Breast Cancer (LOTUS): A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Phase 2 Trial
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(17)30450-3
– volume: 13
  start-page: 1478
  year: 2021
  ident: B47
  article-title: The TCGA Molecular Classification of Endometrial Cancer and Its Possible Impact on Adjuvant Treatment Decisions
  publication-title: Cancers (Basel)
  doi: 10.3390/cancers13061478
– volume: 23
  start-page: 2047
  year: 2018
  ident: B68
  article-title: Rutacecarpine Inhibits Angiogenesis by Targeting the VEGFR2 and VEGFR2-Mediated Akt/mTOR/p70s6k Signaling Pathway
  publication-title: Molecules
  doi: 10.3390/molecules23082047
– volume: 17
  year: 2021
  ident: B3
  article-title: Selective Inhibitors of Mtorc1 Activate 4EBP1 and Suppress Tumor Growth
  publication-title: Nat Chem Biol
  doi: 10.1038/s41589-021-00813-7
– volume: 8
  year: 2011
  ident: B58
  article-title: Autophagy as a Target for Anticancer Therapy
  publication-title: Nat Rev Clin Oncol
  doi: 10.1038/nrclinonc.2011.71
– volume: 125
  year: 2012
  ident: B79
  article-title: TGF-Beta-Induced Activation of mTOR Complex 2 Drives Epithelial-Mesenchymal Transition and Cell Invasion
  publication-title: J Cell Sci
  doi: 10.1242/jcs.095299
– volume: 2
  year: 2012
  ident: B21
  article-title: The Cbio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data
  publication-title: Cancer Discov
  doi: 10.1158/2159-8290.CD-12-0095
– volume: 18
  start-page: 26
  year: 2019
  ident: B117
  article-title: Targeting PI3K in Cancer: Mechanisms and Advances in Clinical Trials
  publication-title: Mol Cancer
  doi: 10.1186/s12943-019-0954-x
– volume: 11
  start-page: 719
  year: 2020
  ident: B12
  article-title: PTEN Alterations and Their Role in Cancer Management: Are We Making Headway on Precision Medicine
  publication-title: Genes (Basel)
  doi: 10.3390/genes11070719
– volume: 17
  start-page: 395
  year: 2020
  ident: B62
  article-title: Targeting Apoptosis in Cancer Therapy
  publication-title: Nat Rev Clin Oncol
  doi: 10.1038/s41571-020-0341-y
– volume: 23
  start-page: 766
  year: 2018
  ident: B118
  article-title: Phase II Study of BEZ235 Versus Everolimus in Patients With Mammalian Target of Rapamycin Inhibitor-Naive Advanced Pancreatic Neuroendocrine Tumors
  publication-title: Oncologist
  doi: 10.1634/theoncologist.2017-0144
– volume: 37
  year: 2019
  ident: B91
  article-title: Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.18.01207
– volume: 4
  year: 2011
  ident: B67
  article-title: PI3K/AKT/mTOR Pathway in Angiogenesis
  publication-title: Front Mol Neurosci
  doi: 10.3389/fnmol.2011.00051
– volume: 19
  start-page: 87
  year: 2018
  ident: B90
  article-title: Buparlisib Plus Fulvestrant in Postmenopausal Women With Hormone-Receptor-Positive, HER2-Negative, Advanced Breast Cancer Progressing on or After mTOR Inhibition (BELLE-3): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(17)30688-5
– volume: 2
  year: 2006
  ident: B64
  article-title: Angiogenesis in Cancer
  publication-title: Vasc Health Risk Manag
  doi: 10.2147/vhrm.2006.2.3.213
– volume: 11
  start-page: 4684
  year: 2020
  ident: B80
  article-title: mTOR-Mediated Cancer Drug Resistance Suppresses Autophagy and Generates a Druggable Metabolic Vulnerability
  publication-title: Nat Commun
  doi: 10.1038/s41467-020-18504-7
– volume: 22
  year: 2016
  ident: B30
  article-title: Analysis of mTOR Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K-AKT-mTOR Pathway Inhibitors
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-15-1110
– volume: 9
  year: 2019
  ident: B87
  article-title: Aurora-A Induces Chemoresistance Through Activation of the AKT/mTOR Pathway in Endometrial Cancer
  publication-title: Front Oncol
  doi: 10.3389/fonc.2019.00422
– volume: 548
  start-page: 297
  year: 2017
  ident: B23
  article-title: Integrative Clinical Genomics of Metastatic Cancer
  publication-title: Nature
  doi: 10.1038/nature23306
– volume: 311
  year: 2011
  ident: B84
  article-title: Inhibitors of mTOR Overcome Drug Resistance From Topoisomerase II Inhibitors in Solid Tumors
  publication-title: Cancer Lett
  doi: 10.1016/j.canlet.2011.06.005
– volume: 34
  year: 2020
  ident: B49
  article-title: PTEN Deletion Drives Aberrations of DNA Methylome and Transcriptome in Different Stages of Prostate Cancer
  publication-title: FASEB J
  doi: 10.1096/fj.201901205RR
– volume: 19
  year: 2013
  ident: B39
  article-title: PIK3CA and AKT1 Mutations Have Distinct Effects on Sensitivity to Targeted Pathway Inhibitors in an Isogenic Luminal Breast Cancer Model System
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-13-0884
– volume: 285
  year: 2010
  ident: B1
  article-title: Mammalian Target of Rapamycin (mTOR): Conducting the Cellular Signaling Symphony
  publication-title: J Biol Chem
  doi: 10.1074/jbc.R109.094003
– volume: 25
  year: 2007
  ident: B109
  article-title: Phase I/II Trial of Temsirolimus Combined With Interferon Alfa for Advanced Renal Cell Carcinoma
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2006.10.5916
– volume: 22
  start-page: 3464
  year: 2021
  ident: B115
  article-title: PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects
  publication-title: Int J Mol Sci
  doi: 10.3390/ijms22073464
– volume: 15
  start-page: 299
  year: 2021
  ident: B85
  article-title: FOXD1-AS1 Regulates FOXD1 Translation and Promotes Gastric Cancer Progression and Chemoresistance by Activating the PI3K/AKT/mTOR Pathway
  publication-title: Mol Oncol
  doi: 10.1002/1878-0261.12728
– volume: 36
  year: 2017
  ident: B2
  article-title: Mtorc1 and Mtorc2 in Cancer and the Tumor Microenvironment
  publication-title: Oncogene
  doi: 10.1038/onc.2016.363
– volume: 18
  start-page: 101
  year: 2019
  ident: B73
  article-title: Crosstalk Between Autophagy and Epithelial-Mesenchymal Transition and its Application in Cancer Therapy
  publication-title: Mol Cancer
  doi: 10.1186/s12943-019-1030-2
– volume: 21
  start-page: 3818
  year: 2020
  ident: B75
  article-title: Phosphorylation Sites in Protein Kinases and Phosphatases Regulated by Formyl Peptide Receptor 2 Signaling
  publication-title: Int J Mol Sci
  doi: 10.3390/ijms21113818
– volume: 6
  start-page: pl1
  year: 2013
  ident: B20
  article-title: Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the Cbioportal
  publication-title: Sci Signal
  doi: 10.1126/scisignal.2004088
– volume: 132
  year: 2018
  ident: B95
  article-title: The Phase 3 DUO Trial: Duvelisib vs Ofatumumab in Relapsed and Refractory CLL/SLL
  publication-title: Blood
  doi: 10.1182/blood-2018-05-850461
– volume: 12
  start-page: 4540
  year: 2021
  ident: B60
  article-title: Galphaq Activation Modulates Autophagy by Promoting Mtorc1 Signaling
  publication-title: Nat Commun
  doi: 10.1038/s41467-021-24811-4
– volume: 21
  start-page: 3285
  year: 2020
  ident: B15
  article-title: Targeting AKT/mTOR in Oral Cancer: Mechanisms and Advances in Clinical Trials
  publication-title: Int J Mol Sci
  doi: 10.3390/ijms21093285
– volume: 20
  start-page: 2767
  year: 2019
  ident: B77
  article-title: TGF-Beta-Mediated Epithelial-Mesenchymal Transition and Cancer Metastasis
  publication-title: Int J Mol Sci
  doi: 10.3390/ijms20112767
– volume: 528
  year: 2020
  ident: B78
  article-title: Hesperetin Inhibit EMT in TGF-Beta Treated Podocyte by Regulation of mTOR Pathway
  publication-title: Biochem Biophys Res Commun
  doi: 10.1016/j.bbrc.2020.05.087
– volume: 18
  year: 2012
  ident: B88
  article-title: A Multicenter Phase I Trial of PX-866, an Oral Irreversible Phosphatidylinositol 3-Kinase Inhibitor, in Patients With Advanced Solid Tumors
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-12-0714
– volume: 288
  year: 2013
  ident: B34
  article-title: Mutations in Critical Domains Confer the Human mTOR Gene Strong Tumorigenicity
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M112.399485
– volume: 9
  year: 2017
  ident: B54
  article-title: Targeting Mtorc2 Component Rictor Inhibits Cell Proliferation and Promotes Apoptosis in Gastric Cancer
  publication-title: Am J Transl Res
– volume: 35
  year: 2017
  ident: B93
  article-title: Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2017.75.4648
– volume: 31
  start-page: 291
  year: 2021
  ident: B44
  article-title: Neddylation of PTEN Regulates its Nuclear Import and Promotes Tumor Development
  publication-title: Cell Res
  doi: 10.1038/s41422-020-00443-z
– volume: 30
  year: 2011
  ident: B61
  article-title: Apoptosis in Cancer: From Pathogenesis to Treatment
  publication-title: J Exp Clin Cancer Res
  doi: 10.1186/1756-9966-30-87
– volume: 502
  year: 2013
  ident: B33
  article-title: Mutational Landscape and Significance Across 12 Major Cancer Types
  publication-title: Nature
  doi: 10.1038/nature12634
– volume: 35
  year: 2016
  ident: B63
  article-title: mTOR Inhibitors Induce Apoptosis in Colon Cancer Cells via CHOP-Dependent DR5 Induction on 4E-BP1 Dephosphorylation
  publication-title: Oncogene
  doi: 10.1038/onc.2015.79
– volume: 78
  year: 2021
  ident: B41
  article-title: Role of Akt Isoforms in Neuronal Insulin Signaling and Resistance
  publication-title: Cell Mol Life Sci
  doi: 10.1007/s00018-021-03993-6
– volume: 23
  year: 2017
  ident: B22
  article-title: Mutational Landscape of Metastatic Cancer Revealed From Prospective Clinical Sequencing of 10,000 Patients
  publication-title: Nat Med
  doi: 10.1038/nm.4333
– volume: 119
  start-page: 7
  year: 2013
  ident: B28
  article-title: Frequency of Mesenchymal-Epithelial Transition Factor Gene (MET) and the Catalytic Subunit of Phosphoinositide-3-Kinase (PIK3CA) Copy Number Elevation and Correlation With Outcome in Patients With Early Stage Breast Cancer
  publication-title: Cancer
  doi: 10.1002/cncr.27608
– volume: 1867
  year: 2020
  ident: B53
  article-title: Crosstalks of GSK3 Signaling With the mTOR Network and Effects on Targeted Therapy of Cancer
  publication-title: Biochim Biophys Acta Mol Cell Res
  doi: 10.1016/j.bbamcr.2019.118635
– volume: 36
  year: 2018
  ident: B98
  article-title: Phosphatidylinositol 3-Kinase Alpha-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-In-Human Study
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2017.72.7107
– volume: 12
  start-page: 2972
  year: 2020
  ident: B16
  article-title: Therapeutic Potential of PI3K/AKT/mTOR Pathway in Gastrointestinal Stromal Tumors: Rationale and Progress
  publication-title: Cancers (Basel)
  doi: 10.3390/cancers12102972
– volume: 123
  year: 2014
  ident: B94
  article-title: Idelalisib, an Inhibitor of Phosphatidylinositol 3-Kinase P110delta, for Relapsed/Refractory Chronic Lymphocytic Leukemia
  publication-title: Blood
  doi: 10.1182/blood-2013-11-535047
– volume: 160
  year: 2021
  ident: B32
  article-title: Worldwide Prevalence of PI3K-AKT-mTOR Pathway Mutations in Head and Neck Cancer: A Systematic Review and Meta-Analysis
  publication-title: Crit Rev Oncol Hematol
  doi: 10.1016/j.critrevonc.2021.103284
– volume: 20
  start-page: 5792
  year: 2019
  ident: B116
  article-title: PI3K/mTOR Pathway Inhibition: Opportunities in Oncology and Rare Genetic Diseases
  publication-title: Int J Mol Sci
  doi: 10.3390/ijms20225792
– volume: 20
  start-page: 74
  year: 2020
  ident: B14
  article-title: The PI3K-AKT Network at the Interface of Oncogenic Signalling and Cancer Metabolism
  publication-title: Nat Rev Cancer
  doi: 10.1038/s41568-019-0216-7
– volume: 52
  year: 2020
  ident: B24
  article-title: Cancer Therapy Shapes the Fitness Landscape of Clonal Hematopoiesis
  publication-title: Nat Genet
  doi: 10.1038/s41588-020-00710-0
– volume: 9
  year: 2019
  ident: B52
  article-title: FKBP4 Connects Mtorc2 and PI3K to Activate the PDK1/Akt-Dependent Cell Proliferation Signaling in Breast Cancer
  publication-title: Theranostics
  doi: 10.7150/thno.35561
– volume: 39
  year: 2021
  ident: B112
  article-title: Phase I or II Study of Ribociclib in Combination With Topotecan-Temozolomide or Everolimus in Children With Advanced Malignancies: Arms A and B of the AcSe-ESMART Trial
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.21.01152
– volume: 11
  start-page: 289
  year: 2011
  ident: B45
  article-title: PTEN Loss in the Continuum of Common Cancers, Rare Syndromes and Mouse Models
  publication-title: Nat Rev Cancer
  doi: 10.1038/nrc3037
– volume: 380
  year: 2019
  ident: B97
  article-title: Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1813904
– volume: 37
  year: 2019
  ident: B96
  article-title: DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.18.00915
– volume: 21
  year: 2020
  ident: B72
  article-title: Guidelines and Definitions for Research on Epithelial-Mesenchymal Transition
  publication-title: Nat Rev Mol Cell Biol
  doi: 10.1038/s41580-020-0237-9
– volume: 39
  year: 2021
  ident: B99
  article-title: Umbralisib, a Dual PI3Kdelta/CK1epsilon Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.20.03433
– volume: 169
  start-page: 381
  year: 2017
  ident: B35
  article-title: AKT/PKB Signaling: Navigating the Network
  publication-title: Cell
  doi: 10.1016/j.cell.2017.04.001
– volume: 157
  year: 2021
  ident: B113
  article-title: First-In-Child Phase I/II Study of the Dual Mtorc1/2 Inhibitor Vistusertib (AZD2014) as Monotherapy and in Combination With Topotecan-Temozolomide in Children With Advanced Malignancies: Arms E and F of the AcSe-ESMART Trial
  publication-title: Eur J Cancer
  doi: 10.1016/j.ejca.2021.08.010
– volume: 22
  start-page: 45
  year: 2020
  ident: B25
  article-title: Frequency and Spectrum of PIK3CA Somatic Mutations in Breast Cancer
  publication-title: Breast Cancer Res
  doi: 10.1186/s13058-020-01284-9
– volume: 6
  start-page: 201
  year: 2021
  ident: B18
  article-title: Small Molecules in Targeted Cancer Therapy: Advances, Challenges, and Future Perspectives
  publication-title: Signal Transduct Target Ther
  doi: 10.1038/s41392-021-00572-w
– volume: 19
  start-page: 618
  year: 2019
  ident: B86
  article-title: Inhibition of PI3K/Akt/mTOR Signaling Pathway Alleviates Ovarian Cancer Chemoresistance Through Reversing Epithelial-Mesenchymal Transition and Decreasing Cancer Stem Cell Marker Expression
  publication-title: BMC Cancer
  doi: 10.1186/s12885-019-5824-9
– volume: 10
  start-page: 659
  year: 2021
  ident: B13
  article-title: Signaling Pathways in Cancer: Therapeutic Targets, Combinatorial Treatments, and New Developments
  publication-title: Cells
  doi: 10.3390/cells10030659
– volume: 26
  start-page: 4100
  year: 2021
  ident: B17
  article-title: Targeting the PI3K/AKT/mTOR Signaling Pathway in Lung Cancer: An Update Regarding Potential Drugs and Natural Products
  publication-title: Molecules
  doi: 10.3390/molecules26134100
– volume: 99
  year: 2021
  ident: B4
  article-title: How Mtorc1 Makes Sense of Nutrients
  publication-title: Kidney Int
  doi: 10.1016/j.kint.2020.07.052
– volume: 1467
  start-page: 3
  year: 2020
  ident: B57
  article-title: Molecular Regulation of Autophagy Machinery by mTOR-Dependent and -Independent Pathways
  publication-title: Ann N Y Acad Sci
  doi: 10.1111/nyas.14305
– volume: 898
  year: 2021
  ident: B11
  article-title: The PI3K/Akt/mTOR Signaling Pathway in Gastric Cancer; From Oncogenic Variations to the Possibilities for Pharmacologic Interventions
  publication-title: Eur J Pharmacol
  doi: 10.1016/j.ejphar.2021.173983
– volume: 75
  year: 2015
  ident: B26
  article-title: Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-15-1654
– volume: 76
  start-page: 36
  year: 2017
  ident: B119
  article-title: Phase Ib Dose-Finding Study of Abiraterone Acetate Plus Buparlisib (BKM120) or Dactolisib (BEZ235) in Patients With Castration-Resistant Prostate Cancer
  publication-title: Eur J Cancer
  doi: 10.1016/j.ejca.2017.01.024
– volume: 27
  year: 2021
  ident: B121
  article-title: Phase I Dose-Escalation Study of the Dual PI3K-Mtorc1/2 Inhibitor Gedatolisib in Combination With Paclitaxel and Carboplatin in Patients With Advanced Solid Tumors
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-21-1402
– volume: 10
  start-page: 52
  year: 2018
  ident: B71
  article-title: The Epithelial-To-Mesenchymal Transition in Cancer
  publication-title: Cancers (Basel)
  doi: 10.3390/cancers10020052
– volume: 7
  year: 2017
  ident: B104
  article-title: A First-In-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients With Solid Tumors
  publication-title: Cancer Discov
  doi: 10.1158/2159-8290.CD-16-0512
– volume: 33
  start-page: 450
  year: 2018
  ident: B27
  article-title: Systematic Functional Annotation of Somatic Mutations in Cancer
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2018.01.021
– volume: 73
  year: 2013
  ident: B83
  article-title: Regulation of FANCD2 by the mTOR Pathway Contributes to the Resistance of Cancer Cells to DNA Double-Strand Breaks
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-12-4282
– volume: 398
  year: 2021
  ident: B105
  article-title: Ipatasertib Plus Abiraterone and Prednisolone in Metastatic Castration-Resistant Prostate Cancer (IPATential150): A Multicentre, Randomised, Double-Blind, Phase 3 Trial
  publication-title: Lancet
  doi: 10.1016/S0140-6736(21)00580-8
– volume: 8
  year: 2018
  ident: B66
  article-title: Unraveling the Role of Angiogenesis in Cancer Ecosystems
  publication-title: Front Oncol
  doi: 10.3389/fonc.2018.00248
– volume: 27
  year: 2021
  ident: B114
  article-title: Sapanisertib Plus Exemestane or Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced or Metastatic Breast Cancer
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-20-4131
– volume: 35
  start-page: 504
  year: 2019
  ident: B50
  article-title: Inhibition of Nuclear PTEN Tyrosine Phosphorylation Enhances Glioma Radiation Sensitivity Through Attenuated DNA Repair
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2019.01.020
– volume: 16
  start-page: 622
  year: 2016
  ident: B38
  article-title: AKT1 (E17K) Mutation Profiling in Breast Cancer: Prevalence, Concurrent Oncogenic Alterations, and Blood-Based Detection
  publication-title: BMC Cancer
  doi: 10.1186/s12885-016-2626-1
– volume: 77
  year: 2020
  ident: B65
  article-title: Tumor Angiogenesis: Causes, Consequences, Challenges and Opportunities
  publication-title: Cell Mol Life Sci
  doi: 10.1007/s00018-019-03351-7
– volume: 165
  year: 2019
  ident: B76
  article-title: Role of AKT and mTOR Signaling Pathways in the Induction of Epithelial-Mesenchymal Transition (EMT) Process
  publication-title: Biochimie
  doi: 10.1016/j.biochi.2019.08.003
– volume: 38
  year: 2020
  ident: B103
  article-title: Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.19.00368
– volume: 122
  year: 2016
  ident: B122
  article-title: A Multicenter, Single-Arm, Open-Label, Phase 2 Study of Apitolisib (GDC-0980) for the Treatment of Recurrent or Persistent Endometrial Carcinoma (MAGGIE Study)
  publication-title: Cancer
  doi: 10.1002/cncr.30286
– volume: 8
  year: 2020
  ident: B40
  article-title: Effect of AKT1 (P. E17K) Hotspot Mutation on Malignant Tumorigenesis and Prognosis
  publication-title: Front Cell Dev Biol
  doi: 10.3389/fcell.2020.573599
– volume: 109
  year: 2012
  ident: B37
  article-title: Disruption of PH-Kinase Domain Interactions Leads to Oncogenic Activation of AKT in Human Cancers
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.1204384109
– volume: 20
  start-page: 755
  year: 2019
  ident: B51
  article-title: mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy
  publication-title: Int J Mol Sci
  doi: 10.3390/ijms20030755
– volume: 62
  year: 2020
  ident: B74
  article-title: Revisiting mTOR and Epithelial-Mesenchymal Transition
  publication-title: Am J Respir Cell Mol Biol
  doi: 10.1165/rcmb.2020-0109ED
– volume: 39
  start-page: 190
  year: 2021
  ident: B101
  article-title: Pan-AKT Inhibitor Capivasertib With Docetaxel and Prednisolone in Metastatic Castration-Resistant Prostate Cancer: A Randomized, Placebo-Controlled Phase II Trial (ProCAID)
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.20.01576
– volume: 59
  start-page: 92
  year: 2019
  ident: B81
  article-title: mTOR: Role in Cancer, Metastasis and Drug Resistance
  publication-title: Semin Cancer Biol
  doi: 10.1016/j.semcancer.2019.07.003
– volume: 18
  year: 2017
  ident: B92
  article-title: Buparlisib and Paclitaxel in Patients With Platinum-Pretreated Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (BERIL-1): A Randomised, Double-Blind, Placebo-Controlled Phase 2 Trial
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(17)30064-5
– volume: 12
  year: 2019
  ident: B69
  article-title: Rapamycin Suppresses Angiogenesis and Lymphangiogenesis in Melanoma by Downregulating VEGF-A/VEGFR-2 and VEGF-C/VEGFR-3 Expression
  publication-title: Onco Targets Ther
  doi: 10.2147/OTT.S205160
– volume: 13
  start-page: 3949
  year: 2021
  ident: B82
  article-title: The Pathogenic Role of PI3K/AKT Pathway in Cancer Onset and Drug Resistance: An Updated Review
  publication-title: Cancers (Basel)
  doi: 10.3390/cancers13163949
– volume: 7
  year: 2021
  ident: B110
  article-title: Effectiveness of Adding Everolimus to the First-Line Treatment of Advanced Breast Cancer in Premenopausal Women Who Experienced Disease Progression While Receiving Selective Estrogen Receptor Modulators: A Phase 2 Randomized Clinical Trial
  publication-title: JAMA Oncol
  doi: 10.1001/jamaoncol.2021.3428
– volume: 382
  start-page: e29
  year: 2020
  ident: B46
  article-title: The Cowden Syndrome
  publication-title: N Engl J Med
  doi: 10.1056/NEJMicm1910478
– volume: 32
  year: 2014
  ident: B31
  article-title: Molecular Genetics of Clear-Cell Renal Cell Carcinoma
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2012.45.2003
– volume: 2
  start-page: 489
  year: 2002
  ident: B36
  article-title: The Phosphatidylinositol 3-Kinase AKT Pathway in Human Cancer
  publication-title: Nat Rev Cancer
  doi: 10.1038/nrc839
– volume: 10
  year: 2020
  ident: B55
  article-title: RICTOR/mTORC2 Affects Tumorigenesis and Therapeutic Efficacy of mTOR Inhibitors in Esophageal Squamous Cell Carcinoma
  publication-title: Acta Pharm Sin B
  doi: 10.1016/j.apsb.2020.01.010
SSID ssj0000650103
Score 2.689292
SecondaryResourceType review_article
Snippet Cancer is a severe public health issue that is a leading cause of mortality globally. It is also an impediment to improving life expectancy worldwide....
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 819128
SubjectTerms cancer
oncogenic alterations
Oncology
PI3K/Akt/mTOR pathway
precision medicine
targeted therapy
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Nb9QwELWqHiouCMpXgCIj9cIhZOPYic2lKhXVttVCqbaiN8uOx6Jqm0XdVKj_vjNJuuwiBBdyyCGxE-uNk3njjzeMbXuvdYhSp4XzZSoNnryqVTpypkb-YbSqaWhg8rkcn8rDM3W2lOqL1oT18sA9cJkopBfGQ55HJWMstQ--rCqDrgcCGKC_L_q8pWCq_wcrSmDQz0tiFGayOGtIsVCI9xSiUPL1JT_UyfX_iWP-vlRyyffsP2IPB9LId_vGPmZr0GyyjckwLf6EfT0-KI6y3Ys2u5p-OeHHyOp-ulvumsAP2jk_mV0CP2_4Hln4mk9_bbmaf8CHAv8GfNJlpeJjNDlW3XnKTvc_TffG6ZArIa2V0G2qYk5KcnUIQaCXjwYKMLH2wlWAuEOZl7oqvEHIXMxj4XIBoRwJJyigqOriGVtvZg28YNwg1k6VyBu1l-Cic96THvkI8FAhJCy7R87Wg5A45bO4tBhQENaWsLaEte2xTti7RY0fvYjGX8p-JGMsypH8dXcBO4UdOoX9V6dI2Nt7U1r8XGgOxDUwu5lb5H8GWZ6QKmHPe9MuXkVDYLSvOGHVitFX2rJ6pzn_3klya6MraeTL_9H4V-wB4UEL3YR8zdbb6xvYQubT-jddJ78Ds2MBXQ
  priority: 102
  providerName: Directory of Open Access Journals
Title PI3K/Akt/mTOR Pathway and Its Role in Cancer Therapeutics: Are We Making Headway?
URI https://www.ncbi.nlm.nih.gov/pubmed/35402264
https://www.proquest.com/docview/2649256245
https://pubmed.ncbi.nlm.nih.gov/PMC8987494
https://doaj.org/article/234b29be11f54ff68bdb6779224ede9e
Volume 12
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3db9MwELdgSIgXxPfCx2QkXnjI2jh2YiOhaUyMDlQYUyv6FtnxGSZKAm0m2H_PXZJ1FFWIPPgh8efdOfc7f9wx9sw5rX2QOk6ty2JpMHGqVPHQmhLxh9GqpKWB8ftsNJVvZ2p2eT26J-Byo2lH8aSmi_nurx_nezjhX5LFifp2EOqKnBEKsUvWh9BX2TXUSznFMxj3YL_7LysKakDR5kQqYyPTWbdvubGSNT3VuvPfhEH_Pkr5h246vMVu9qCS73dScJtdgeoOuz7ut83vso_HR-m7wf7XZvBt8uGEHyPq-2nPua08P2qW_KSeAz-t-AFJwIJPLq9kLV9gpcA_AR-3Uav4CEUCi-7dY9PD15ODUdzHUohLJXQTq5CQp7nSey8QBQQDKZhQOmFzQL5AlmQ6T53xYGxIQmoTAT4bCivI4MjL9D7bquoKthk3kCRWZYgrtZNgg7XOkb_yIeCjvI_Y4IJyRdk7Gqd4F_MCDQ6idUG0LojWRUfriD1flfjeOdn4R95XxIxVPnKP3b6oF5-LfrYVyF8njMOOBiVDwI56l-W5QbwCOEKI2NMLVhY4nWiPxFZQny0LxIcGUaCQKmIPOtaumqIlMrp3HLF8jelrfVn_Up1-aV12a6NzaeTD_2j3EbtBw6VzbkI-ZlvN4gyeIPBp3E67YIDpm1my08r2bwuZAag
linkProvider Scholars Portal
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=PI3K%2FAkt%2FmTOR+Pathway+and+Its+Role+in+Cancer+Therapeutics%3A+Are+We+Making+Headway%3F&rft.jtitle=Frontiers+in+oncology&rft.au=Peng%2C+Yan&rft.au=Wang%2C+Yuanyuan&rft.au=Zhou%2C+Cheng&rft.au=Mei%2C+Wuxuan&rft.date=2022-03-24&rft.issn=2234-943X&rft.eissn=2234-943X&rft.volume=12&rft.spage=819128&rft_id=info:doi/10.3389%2Ffonc.2022.819128&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2234-943X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2234-943X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2234-943X&client=summon